tbuckley/cabot-search huggingface dataset:
Endoscopic salvage treatment for local failure after definitive chemoradiotherapy (CRT) for esophageal cancer (EC)
Authors: M. Muto, S. Hattori, T. Yano, K. Minashi, Y. Hamamoto, K. Mera, T. Doi, A. Ohtsu, S. Yoshida
Journal: Journal of Clinical Oncology (2005)

4051 Background: Local failure after definitive CRT for EC is the major treatment issue. Although salvage surgical resection is the only curative treatment option, this approach is associated with high mortality and morbidity rates and can be indicated in selected patients (pts). Since some pts had local failure alone without metastasis after CRT, local treatment such as endoscopic mucosal resection (EMR) and photodynamic therapy (PDT) could have curative potential. We evaluated the safety and preliminary efficacy of endoscopic salvage treatment. Methods: Endoscopic salvage treatment was indicated if pts fulfilled the following criteria: 1) residual or recurrent lesions in the esophagus after definitive CRT, 2) N0M0 clinically defined by computed tomography and endoscopic ultrasound (EUS) at the time of salvage; 3) refusal salvage surgery; and 4) written informed consent. Treatment choice of EMR or PDT depended on the estimated depth of the lesions by EUS (EMR for T1a; PDT for T1b or T2). Toxicity was estimated by NCI-CTC version2. Results: Between Feb. 1998 and Feb. 2004, 49 of 444 pts who received CRT underwent endoscopic salvage treatment (EMR: 29, PDT: 20) for local failure in our hospital. Baseline clinical stages before CRT were: T1 (12), T2 (5), T3 (28), T4 (4); N0 (22), N1 (4); M0 (44), M1a (1), M1b (4). Twenty-four pts had local residual tumors and 25 had local recurrence after achieving a complete response to CRT. Thirty-nine were estimated with T1 tumors and the remaining with T2 by EUS. Fever (grade1) and chest pain (grade 1) were the main toxicity, but manageable. Clinically, 69% (20/29) and 59% (13/22) of the lesions disappeared by EMR and PDT, respectively. There was no treatment-related death. With a median follow-up of 12 (3–81) months after endoscopic salvage treatment, 1- and 3-year overall and progression-free survival rates were 71.3% and 52.7%, 45.3% and 45.3%, respectively. Seven pts (14%) developed lymph node or distant metastasis. Four pts died of other disease. Conclusions: Endoscopic local treatment could be one of the curative salvage treatment options with low mortality and morbidity for local failure after definitive CRT. We plan a phase II study of salvage endoscopic treatment. No significant financial relationships to disclose.
Association of Asymptomatic Bradycardia With Incident Cardiovascular Disease and Mortality
Authors: Ajay Dharod, Elsayed Z. Soliman, Farah Dawood, Haiying Chen, Steven Shea, Saman Nazarian, Alain G. Bertoni
Journal: JAMA Internal Medicine (2016)

Bradycardia has been associated with lower cardiovascular disease (CVD) risk in selected populations. There is a paucity of information available about heart rate (HR) less than 50 beats per minute (bpm) among middle-aged or older adults.To determine whether asymptomatic bradycardia was associated with a lower cardiovascular risk profile, less subclinical atherosclerosis, and decreased incident CVD and mortality.This retrospective analysis includes 6733 participants of the Multi-Ethnic Study of Atherosclerosis, which recruited men and women free of clinical cardiovascular disease ages 45 to 84 years from 2000 to 2002 and followed them over 10 years for incident CVD events and mortality. The HR was measured by baseline electrocardiogram. The analysis was performed in June 2014.The association between HR categories with CVD events and all-cause mortality were examined using Cox proportional hazards models adjusted for potential confounders and mediators.The 6733 participants had a mean (SD) age of 62 (10.2) years; 47% were male. The mean (SD) HR was 63 (9.5) bpm among the 5831 participants not taking an HR-modifying drug; 5.3% had an HR lower than 50 bpm. Preliminary results revealed significant interaction for HR categories according to use of HR-modifying drugs for mortality (P = .002); thus, all further analyses were stratified. An HR of less than 50 bpm was not associated with incident CVD in either subgroup (participants taking or not taking HR-modifying drugs). Among participants not taking HR-modifying drugs, the fully adjusted mortality risk was not different for an HR less than 50 bpm (hazard ratio, 0.71 [95% CI, 0.41-1.09]; P = .12) and increased among those with an HR greater than 80 bpm (hazard ratio, 1.49 [95% CI, 1.08-2.05]; P = .01) (reference HR, 60-69 bpm). Among the 902 participants taking HR-modifying drugs there was an elevated mortality risk associated with an HR less than 50 bpm (hazard ratio, 2.42 [95% CI, 1.39-4.20]; P = .002) and with an HR greater than 80 bpm (hazard ratio, 3.55 [95% CI, 1.65-7.65]; P = .001) (reference HR, 60-69 bpm).In a contemporary, community-based cohort, bradycardia was generally not associated with incident CVD or mortality except for a potential adverse association between bradycardia among those taking HR-modifying drugs.
Abstract 19492: Novel Assessment of Pulmonary and Systemic Pressures During Treadmill Testing via Implantable Telemetry in a Rat Model of Pulmonary Arterial Hypertension
Authors: Abigail Zinn, Rachel Novack, Amanda Fisher, Robert Presson, Dmitry Zaretsky, Daniel Rusyniak, Tim Lahm, Mary Beth Brown
Journal: Circulation (2014)

Objectives: 1) To determine if pulmonary arterial pressures (PAP) may be measured simultaneously with systemic blood pressures (BP) during exercise testing in laboratory rats using implantable telemetry; and 2) To determine the relationship of exercise intensity to acute PAP exercise responses over the course of PAH development. Methods: A specialized implantable transmitter (Data Sciences International); via telemetry following thoracotomy with right ventricular (RV) and abdominal aortic catheter positioning, respectively enabled simultaneous systolic, diastolic and mean PAP and BP recordings. Following recovery, an incremental treadmill test measured maximal aerobic capacity (VO 2 max) via analysis of expired gases. Steady state exercise testing was then performed for 3 different submaximal relative intensities: 50, 75, and 90% VO 2 max. Pressures were recorded during each test, as well as pre- and post- exercise. At 2.5 weeks following monocrotaline (MCT, 40 mg/kg) administration (mild PH) and 7 weeks post-MCT (advanced PH), VO 2 max and steady-state exercise tests were repeated. Results: Compared to pre-MCT, at 2.5 weeks post-MCT systolic PAP increased from 25 to 41 mmHg at rest; from 105 to 117 mmHg at peak exercise; and from 40 to 58 mmHg, 46 to 65 mmHg, and 55 to 75 mmHg during running at 50, 75, and 90% VO 2 max, respectively. At 7 weeks post-MCT, PAP further increased at rest (to 59 mmHg), and during steady state running (to 69, 70, and 73 mmHg, at 50, 75, and 90% VO 2 max, respectively). During recovery from steady state exercise, the fall in PAP occurred more rapidly post-MCT, bringing PAP to even lower than resting from 10 min to 2h into recovery. Conclusions: Using implantable telemetry we have accomplished dual pressure recordings during serial exercise tests before and after PAH induction. The rise in PAP relative to exercise intensity is steeper in PAH but is accompanied by a post-exercise window of normalized PAP, which may be attributed to pronounced acute pulmonary endothelial activation. Future work will investigate how these acute effects translate to wall stress and RV remodeling with chronic exercise training and may allow for optimized exercise prescription for patients affected with PAH.
High-performance dendritic contrast agents for X-ray computed tomography imaging using potent tetraiodobenzene derivatives
Authors: Suyeon You, Hye-youn Jung, Chaewoon Lee, Yun Hui Choe, Ju Young Heo, Gil-Tae Gang, Sang-Kyung Byun, Won Kon Kim, Chul-Ho Lee, Dong-Eog Kim, Young Il Kim, Yoonkyung Kim
Journal: Journal of Controlled Release (2016)
Relationship between compliance with imatinib mesylate and medical costs for patients with CML and GIST
Authors: R. Halpern, V. Barghout, D. Williams
Journal: Journal of Clinical Oncology (2007)

6618 Background: Imatinib mesylate, an oral tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), has been found both effective and cost-effective. This study examines the relationship between imatinib compliance and health care costs for patients (pts) with CML and GIST. Methods: This retrospective study used claims data from a large national US health plan. Pts had =2 imatinib claims from 6/1/01–3/31/05; =1-year follow-up after the 1 st imatinib claim; and diagnosis of CML (ICD9 205.1x) or GIST (ICD9 159.0, 159.8, 159.9 or evaluation of claims and attribution of GIST by independent hematologist/oncologist). Compliance was measured with a medication possession ratio ((days of imatinib during follow-up / days of follow- up)*100). Compliance categories were good, =90%; medium, 70–89.9%; poor, &lt;70%. Total follow-up medical and health care (medical + pharmacy) costs were measured and compared across compliance categories; t-tests compared mean costs. Results: 374 CML and 91 GIST pts had mean age of 52.1 ± 14.0 years. 274 (59%) pts were male. 234 (50%) of pts had 12–24 months follow-up; 231 (50%) had 25–57 months. Mean and median compliance across all pts were 69.4% and 79.7%, respectively. 122 (33%) CML and 32 (35%) GIST pts had good compliance; 149 (40%) CML and 42 (46%) GIST pts had poor compliance. Mean medical costs across all pts were lower and less variable with good compliance ($22,882 ± 22,791) than with medium ($40,366 ± 68,186), p=0.007) and poor ($104,961 ± 190,559), p&lt;0.001). Similarly, mean medical costs for CML pts with good, medium, and poor compliance were $21,456 (±22,127), $41,537 (±72,238, p=0.008), and $117,004 (±211,292, p&lt;0.001), respectively. Mean medical costs for GIST pts were: good=$28,318 (±24,781); medium=$33,270 (±35,356, p=0.584); and poor=$62,235 (±68,751, p&lt;0.001). Mean total health care costs were 21.7% lower for pts with good compliance relative to those with poor. Conclusions: Good imatinib compliance was associated with significantly lower medical costs. Mean total medical costs were 78% lower with good compliance relative to poor. Compliance is an important treatment issue for both clinical and medical cost outcomes. No significant financial relationships to disclose.
Long-term protective effect of mature DC-LAMP<sup>+</sup> dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study
Authors: R. A. Scolyer, B. Elliott, S. Suciu, A. M. Eggermont, R. Mackie, C. Robert, J. F. Thompson, E. Angevin, M. G. Cook, A. Spatz
Journal: Journal of Clinical Oncology (2007)

8509 Background: In a previous immunohistochemical study of dendritic cells (DCs) in sentinel lymph nodes (SLNs) draining regressing melanomas we found that the accumulation of mature DC-LAMP+ DCs in SLNs was associated with local expansion of antigen- specific memory effector cytotoxic T lymphocytes and the absence of metastasis in downstream lymph nodes. The aim of this study was to investigate the prognostic importance of the maximal density of mature DCs in SLNs using the anti-DC LAMP antibody. Methods: 458 consecutive patients with micrometastatic melanoma within SLNs and 3 yrs follow-up after SLN procedure or death within 3 yrs were eligible for analysis. Semi-quantitative evaluation of mature DC DC-LAMP+ maximum density was made as follows: the slide was examined at intermediate magnification (x100) to select the area containing the maximum number of DC-LAMP+ DCs, the number of DC-LAMP+ cells per mm 2 was then determined at high magnification (x400) in 3 mm 2 in high density areas. Results were reported as number of cells /mm2. The maximal density of mature DC-LAMP+ DCs was evaluated by three independent observers and categorized into three classes (&lt;100/mm 2 , 100- &lt;200/mm 2 , ≥200/mm 2 ) according to previously reported cutpoints. Results: There was excellent inter-observer reproducibility for maximum density of mature DC-LAMP+ DCs scores (kappa score = 0.82). There were differences in the maximal density scores and staining intensity according to the center (P&lt;0.001). The higher the mature DC density in the SLN the longer the duration of survival [p=0.047; hazard ratio (95% CI) = 0.70 (0.50–1.00)]. Conclusions: This study is the first to report the prognostic value of DC-LAMP+ DC counts in SLNs containing metastatic melanoma. Patients with a high density of mature DCs (≥200/mm 2 ) have the lowest risk of death. It also provides evidence that a lack of DC maturation in the SLNs is important in biological facilitation of melanoma progression. No significant financial relationships to disclose.
Plasma quantification of leptin and ubiquitin in patients with advanced non-small cell lung cancer: Correlation with progression and nutritional status
Authors: C. Camps, R. Sirera, A. Blasco, A. Cabrera, V. Iranzo, M. Gil, D. Cayuela, D. Balaguer, C. Caballero, A. Berrocal
Journal: Journal of Clinical Oncology (2008)

20618 Background: Tumour cachexia is a complex syndrome characterized by a progressive weight loss. Ubiquitin and leptin are important mediators of protein and lipid turnover in muscle and adipose tissue. The objective of this study was to investigate the usefulness of plasma measurements of leptin and ubiquitin as prognostic marker of cachexia in advanced non-small cell lung cancer (NSCLC) patients. Methods: The cohort consisted in 50 patients with advanced NSCLC that received first-line therapy with platinum combinations. Patients received a median of 6 chemotherapy cycles and none nutritional supplementations. Concentration levels of leptin and ubiquitin were determined in plasma by a sandwich quantitative ELISA in the baseline, before therapy. In parallel were analysed 70 age-matched controls. Results: Median age was 61, range [20–78], 74% males, 37% stage IIIB and 63% IV and 86% PS 0–1. The histological subtypes were: 34% squamous cell carcinoma, 34% adenocarcinoma, 26% undifferentiated. Median leptin and ubiquitin levels differ significantly between controls and patients: leptin 14.479 vs 3.735 pg/ml (p=0.035) and ubiquitin 0.0686 vs 0.0294 AUs (p=0.018). Median leptin levels were higher in women 15.334 vs 3.160 pg/ml (p=0.002). Leptin and ubiquitin levels increased with the number of chemotherapy cycles but were only significant for leptin (p=0.044). There were not differences in basal or sequential levels of leptin and ubiquitin if we divided the cohort in patients with or without anorexia. Splitting the cohort in two groups attending to median levels of leptin and ubiquitin TTP and OS curves were not significantly different. Leptin and ubiquitin levels are not correlated with other clinical or anthropometrical variables. Conclusions: Leptin and ubiquitin levels are significabtly different between controls and patients but there is not a correlation between patient’s clinical characteristics and plasma levels of these cachexia mediators. No significant financial relationships to disclose.
Increased apoptotic activity is associated with hospital mortality and disruption in lipid homeostasis in acute-on-chronic liver failure.
Authors: Mark McPhail, Evangelos Triantafyllou, Debbie Shawcross, Charalambos G. Antoniades, Mattew R. Lewis, Elizabeth Want, Vishal C. Patel, Yasmin Pasha, Daniel Abeles, William Bernal, Elaine Holmes, Julia Wendon, Simon D. Taylor-Robinson
Journal: Hepatology (2013)
Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients.
Authors: B Fisher
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.3.1027 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8622007 Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. B FisherxB FisherSearch for articles by this author Show More Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA. https://doi.org/10.1200/JCO.1996.14.3.1027 First Page PDF © 1996 by American Society of Clinical Oncology
Long-Term Outcome of Administration of c-kit <sup>POS</sup> Cardiac Progenitor Cells After Acute Myocardial Infarction
Authors: Xian-Liang Tang, Qianhong Li, Gregg Rokosh, Santosh K. Sanganalmath, Ning Chen, Qinghui Ou, Heather Stowers, Greg Hunt, Roberto Bolli
Journal: Circulation Research (2016)

Cardiac progenitor cells (CPCs) improve left ventricular remodeling and function after acute or chronic myocardial infarction. However, the long-term (>5 weeks) effects, potential tumorigenicity, and fate of transplanted CPCs are unknown.To assess the outcome of CPC therapy at 1 year.Female rats underwent a 90-minute coronary occlusion; 4 hours after reperfusion, they received intracoronarily vehicle or 1 million male, syngeneic CPCs. One year later, CPC-treated rats exhibited smaller scars and more viable myocardium in the risk region, along with improved left ventricular remodeling and regional and global left ventricular function. No tumors were observed. Some transplanted (Y-chromosome(POS)) CPCs (or their progeny) persisted and continued to proliferate, but they failed to acquire a mature cardiomyocyte phenotype and were too few (4-8% of nuclei) to account for the benefits of CPC therapy. Surprisingly, CPC transplantation triggered a prolonged proliferative response of endogenous cells, resulting in increased formation of endothelial cells and Y-chromosome(NEG) CPCs for 12 months and increased formation, for at least 7 months, of small cells that expressed cardiomyocytic proteins (α-sarcomeric actin) but did not have a mature cardiomyocyte phenotype.The beneficial effects of CPCs on left ventricular remodeling and dysfunction are sustained for at least 1 year and thus are likely to be permanent. Because transplanted CPCs do not differentiate into mature myocytes, their major mechanism of action must involve paracrine actions. These paracrine mechanisms could be very prolonged because some CPCs engraft, proliferate, and persist at 1 year. This is the first report that transplantation of any cell type in the heart induces a proliferative response that lasts at least 1 year. The results strongly support the safety and clinical utility of CPC therapy.
Complementary Role of Arm Circumference to Body Mass Index in Risk Stratification in Heart Failure
Authors: Kentaro Kamiya, Takashi Masuda, Yuya Matsue, Takayuki Inomata, Nobuaki Hamazaki, Ryota Matsuzawa, Shinya Tanaka, Kohei Nozaki, Emi Maekawa, Chiharu Noda, Minako Yamaoka-Tojo, Atsuhiko Matsunaga, Tohru Izumi, Junya Ako
Journal: JACC Heart Failure (2016)
THE TOXICITY AND TRYPANOCIDAL ACTIVITY OF SODIUM ARSPHENAMIN
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and safety of concurrent chemoradiotherapy (CCR) for unresectable locally advanced (ULA) head and neck squamous cell carcinoma (HNSCC)
Authors: G. Castro, I. M. L. Snitcovsky, E. M. Gebrim, G. M. Leitao, C. N. Rocha, W. Nadalin, A. R. Ferraz, M. H. H. Federico
Journal: Journal of Clinical Oncology (2005)

5589 Background: Concurrent radiotherapy (RT) and cisplatin (P) can be considered as the standard treatment for ULA-HNSCC. Toxicity is a critical issue. We prospectively evaluated the efficacy and safety of CCR in our institution. Methods: Eligible pts: ULA-HNSCC; M0; age 18–70 y; ECOG PS 0–2; adequate organ function; measurable disease (RECIST); signed informed consent. CCR: RT 70 Gy (2 Gy/d, 5 times/wk, 7 wks) and P 100 mg/m2 on D1, D22, D43. Analysis was intention-to-treat. Results: 32 pts were included (mar/03-sep/04): 27 male; median age 53 y; 3 PS0, 28 PS1, 1 PS2; median body mass index 19.3 kg/m2; median hemoglobin (Hb) 12.4 g/dL; median serum albumin 4.0 g/L; tumor site: 14 oral cavity, 11 oropharynx, 5 hypopharynx, 2 larynx; stage (AJCC 2002): 29 T4, 13 N3; grade: 11 G1, 17 G2, 1 G3. Median RT delivered: 70 Gy in primary tumor and 50 Gy in cervical lymph nodes; median RT duration: 62 d (30–88). Median number of cycles of P: 2; 31, 29 and 15 pts received cycles 1, 2 and 3. Mean P dose intensity: 27.3±9.6 mg/m2/wk (64% of the planned 300 mg/m2/7wk). Response rate: 37.5% (4 complete, 8 partial, 4 progressive disease, 1 stable disease). Six pts died during the median follow-up of 7.8 mo. Median overall survival: 11.3 mo; median progression-free survival: 7.5 mo (Kaplan-Meier). Main G3/4 toxicities (NCI-CTC 2.0): nausea (4), vomiting (3), pharyngeal dysphagia (15), oral mucositis (23), dermatitis (7), infection (4), peripheral neuropathy (1), anemia (7), leucopenia (5), neutropenia (5), lymphopenia (7); 13 pts received red blood cell transfusion (median: 2 units) to maintain Hb≥10 g/dL; 18 pts needed enteral nutrition. Mean weight loss: 4.8 kg (p=0.0003, t-test). There was significant reduction in pain scores (numeric scale) before (median: 6) and after (median: 0; p=0.001-Wilcoxon) CCR. Preliminary data showed that quality of life (QoL) did not change after CCR in global QoL (p=0.785-Wilcoxon), pain (p=0.102), swallowing (p=0.680) and social eating (p=0.074) domains (EORTC H&N35 validated in Brazilian Portuguese, 5 pts). Conclusions: CCR presented high toxicity, despite aggressive clinical support. Pain control was observed, even with a low RR. Supported in part by FAPESP 03/05842–8. No significant financial relationships to disclose.